Wedbush Cuts PT on Garmin from $60 to $55 (GRMN)
Get Alerts GRMN Hot Sheet
Price: $310.20 --0%
Rating Summary:
7 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 10 | New: 16
Rating Summary:
7 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 10 | New: 16
Join SI Premium – FREE
Wedbush Morgan lowers its price target on Garmin (Nasdaq: GRMN) from $60 to $55 and reiterates its Buy rating.
The firm said it was surprised with Garmin's strong margin levels during Q1, and believes this slightly offset revenues and EPS that were slightly lower-than-expected. Additionally, Wedbush notes Garmin management's confidence in being able to achieve its original FY08 guidance.
Wedbush calls Garmin a "good value play" due to a "very attractive valuation and continued growth in revenue and profits."
Notably, Wedbush's new price target on Garmin still represents about a 31% return from today's price of around $42.
Garmin, Ltd. and its subsidiaries design, develop, manufacture, and market global positioning system (GPS)-enabled products and other related navigation, communications, and information products worldwide. [BCS]
The firm said it was surprised with Garmin's strong margin levels during Q1, and believes this slightly offset revenues and EPS that were slightly lower-than-expected. Additionally, Wedbush notes Garmin management's confidence in being able to achieve its original FY08 guidance.
Wedbush calls Garmin a "good value play" due to a "very attractive valuation and continued growth in revenue and profits."
Notably, Wedbush's new price target on Garmin still represents about a 31% return from today's price of around $42.
Garmin, Ltd. and its subsidiaries design, develop, manufacture, and market global positioning system (GPS)-enabled products and other related navigation, communications, and information products worldwide. [BCS]
You May Also Be Interested In
- BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
- CrowdStrike (CRWD) PT Raised to $230 at Wells Fargo
- Rapport Therapeutics (RAPP) PT Raised to $75 at Raymond James
Create E-mail Alert Related Categories
Analyst Comments, Insiders' BlogRelated Entities
Wedbush Morgan, Scopia CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share